He is the Co-inventor of the anti-infective – Enmetazobactam; a techno-commercial Enabler, Influencer, Intrapreneur, and an R&D Biologist with broad research experience who enjoys smooth jazz. Trained as a Clinical Microbiologist he progressed into basic & applied research discovering novel anti-infectives and characterizing several microbial genes & proteins. He has translated scientific accomplishments and leadership through patents and publications Know more (search: paul-satyaseela)

Inspired by Louis Pasteur’s biography in his seventh grade, he was introduced to the world of microbes. The idea of an invisible and intangible world fascinated him and kindled a deep passion for the subject, inspiring him to Major in Medical Microbiology (Kasturba Medical College-MAHE, Mangalore),  up until his Doctorate (Gnanaganga, India) in a project that was supported by Dr. Jean-Claire Lee of Harvard Medical School, Boston USA.

As a Post-Doctoral Fellow, he was further trained in infectious diseases, specifically in molecular mechanisms of the pathogenesis of neonatal microbial meningitis at Johns Hopkins School of Medicine, Baltimore, USA, and in the role of A. actinomycetemcomitans in pathogenesis of atherosclerosis at Umeå University, Sweden.  He was the ORISE Fellow at CBER, US FDA, Bethesda, USA working on Reverse vaccinology of N. meningitidis, & as Industrial Fellow in Anti-infectives New Drug Discovery program (DRF8417) at Dr. Reddy’s R&D, India.

He led the Anti-infectives (Biology) Discovery Research at Orchid Pharma (Chennai), co-invented several pre-clinical candidates in anti-bacterial and anti-fungal space, incl. leading the Enmetazobactam program at Orchid Pharma, Chennai, and out-licensing it at Phase-1 to Allecra GmbH that completed Phase-3 Trials (Feb 2020).

He became the AMR Stewardship Champion (Gordon Conference, 2008), and has led several initiatives, and is the Subject Matter Expert of the AMR Cell of the Govt. Karnataka (India), and Member of the AMR Committee of the Infectious Diseases Society of America (USA). He is active through several organizations such as Antibiotic Action (Laura Piddock), AMR Insights (Maarten von Dongen), CoVid-19 Global Coordination etc. promoting AMR Stewardship.

He has strong proficiency in creating synergies and opportunities for external alliances leading cross-functional teams for timely delivery of proprietary, and collaborative projects translating into milestones (incl. an 8-year collaborative project in anti-infectives with Merck, USA), was a key contributor in Orchid’s Zosyn victory against Wyeth (now Pfizer).  Has proven techno-commercial skills leading the Project management division of 5 therapeutic areas (incl. Metabolic Disorders, Oncology, Inflammation, & CNS).

He also led post-graduate Evidence-based medical research at St. Martha’s Hospital, Bangalore, in addition to continuing to advise several Companies.

Maneesh Paul has been the Founder and CEO of Microvioma since August 2022